| Literature DB >> 30192894 |
Duong Bich Thuy1,2, James Campbell1,3, Le Thanh Hoang Nhat1, Nguyen Van Minh Hoang1, Nguyen Van Hao2,4, Stephen Baker1,3,5, Ronald B Geskus1,3, Guy E Thwaites1,3, Nguyen Van Vinh Chau4,6, C Louise Thwaites1,3.
Abstract
Data concerning intensive care unit (ICU)-acquired bacterial colonization and infections are scarce from low and middle-income countries (LMICs). ICU patients in these settings are at high risk of becoming colonized and infected with antimicrobial-resistant organisms (AROs). We conducted a prospective observational study at the Ho Chi Minh City Hospital for Tropical Diseases, Vietnam from November 2014 to January 2016 to assess the ICU-acquired colonization and infections, focusing on the five major pathogens in our setting: Staphylococcus aureus (S. aureus), Escherichia coli (E. coli), Klebsiella spp., Pseudomonas spp. and Acinetobacter spp., among adult patients with more than 48 hours of ICU stay. We found that 61.3% (223/364) of ICU patients became colonized with AROs: 44.2% (161/364) with rectal ESBL-producing E. coli and Klebsiella spp.; 30.8% (40/130) with endotracheal carbapenemase-producing Acinetobacter spp.; and 14.3% (52/364) with nasal methicillin-resistant S. aureus. The incidence rate of ICU patients becoming colonized with AROs was 9.8 (223/2,276) per 100 patient days. Significant risk factor for AROs colonization was the Charlson Comorbidity Index score. The proportion of ICU patients with HAIs was 23.4% (85/364), and the incidence rate of ICU patients contracting HAIs was 2.3 (85/3,701) per 100 patient days. The vascular catheterization (central venous, arterial and hemofiltration catheter) was significantly associated with hospital-acquired bloodstream infection. Of the 77 patients who developed ICU-acquired infections with one of the five specified bacteria, 44 (57.1%) had prior colonization with the same organism. Vietnamese ICU patients have a high colonization rate with AROs and a high risk of subsequent infections. Future research should focus on monitoring colonization and the development of preventive measures that may halt spread of AROs in ICU settings.Entities:
Mesh:
Year: 2018 PMID: 30192894 PMCID: PMC6128614 DOI: 10.1371/journal.pone.0203600
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Inclusion of patients, taking surveillance swabs, and outcomes.
General patient characteristics during ICU stay.
| Age (yr)–median (IQR) | 46 (33–60) |
|---|---|
| | 265 (72.8) |
| | 99 (27.2) |
| | 242 (66.5) |
| | 122 (33.5) |
| 0 (0–1) | |
| | 247 (67.8) |
| | 73 (20.1) |
| | 24 (6.6) |
| | 20 (5.5) |
| 8 (3–14) | |
| | 118 (32.4) |
| | 134 (36.8) |
| | 112 (30.8) |
| | 204 (56.0) |
| | 75 (20.6) |
| | 45 (12.4) |
| | 17 (4.7) |
| | 23 (6.3) |
* Local infections included pneumonia (25 cases), cellulitis (4 cases), UTI (15 cases), and spontaneous bacterial peritonitis (1 cases)
# Internal medicine diseases included kidney failure (6 cases), myocarditis (3 cases), myocardial infarction (6 cases), atrial fibrillation (3 cases), malignant hypertension (2 cases), diabetic ketoacidosis (2 cases) and epilepsy (2 cases).
Antimicrobial resistance of colonized bacteria (in percentage).
| Antimicrobials | |||||
|---|---|---|---|---|---|
| Amoxcillin-clavulanic acid | 924 (59.6) | 260 (29.1) | |||
| Ceftazidime | 881 (56.8) | 256 (28.6) | 539 (97.1) | 101 (22.1) | |
| Ceftriaxone | 881 (56.8) | 256 (28.6) | 539 (97.1) | ||
| Cefepime | 811 (52.3) | 213 (23.8) | 539 (97.1) | 87 (19.0) | |
| Ticarcillin-clavulanate | 984 (63.5) | 277 (30.9) | 537 (96.8) | 330 (72.1) | |
| Piperacillin-tazobactam | 815 (52.6) | 219 (24.5) | 537 (96.8) | 81 (17.7) | |
| Ofloxacin | 767 (49.5) | 131 (14.6) | |||
| Ciprofloxacin | 227 (60.1) | 780 (50.3) | 183 (20.4) | ||
| Levofloxacin | 221 (58.5) | 352 (63.4) | 56 (12.2) | ||
| Sulfamethoxazole-trimethoprim | 19 (5.0) | 1,102 (71.1) | 335 (37.4) | 302 (54.4) | 438 (95.6) |
| Amikacin | 25 (1.6) | 27 (3.0) | 215 (38.7) | 23 (5.0) | |
| Gentamycin | 23 (5.0) | ||||
| Ertapenem | 42 (2.7) | 32 (3.6) | |||
| Imipenem | 33 (2.1) | 32 (3.6) | 371 (66.8) | 202 (44.1) | |
| Meropenem | 26 (1.7) | 32 (3.6) | 371 (66.8) | 183 (40.0) | |
| Colistin | 27 (1.7) | 44 (4.9) | 6 (1.1) | 0 | |
| Penicillin | 368 (97.4) | ||||
| Oxacillin | 275 (72.8) | ||||
| Vancomycin | 0 | ||||
| Erythromycin | 265 (70.1) | ||||
| Rifampicin | 30 (7.9) | ||||
| Clindamycin | 269 (71.1) |
Fig 2Number of patients became colonized during ICU stay.
ICU patients became colonized with sensitive organisms are represented by the black color, and those with AROs are shown by the grey color.
Univariate hazard ratios for risk factors for acquired colonization with AROs, according to Cox regression analysis.
| Variables | Nasal colonization (N = 123) | Rectal colonization (N = 199) | Endotracheal colonization (N = 80) | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Admission for tetanus disease | 0.40 (0.27–0.60) | <0.001 | 0.37 (0.27–0.51) | <0.001 | 0.63 (0.35–1.13) | 0.12 |
| Charlson Comorbidity Index score | 1.25 (1.08–1.44) | 0.003 | 1.24 (1.12–1.37) | <0.001 | 1.45 (1.09–1.93) | 0.01 |
| Admission colonization status | ||||||
| Admission nasal colonization | 0.65 (0.37–1.12) | 0.12 | - | - | - | - |
| Admission rectal colonization | - | - | 1.12 (0.76–1.64) | 0.57 | - | - |
| Admission endotracheal colonization | - | - | - | - | 0.86 (0.47–1.57) | 0.63 |
| Receipt of antimicrobial treatment on admission | 1.96 (1.31–2.95) | 0.001 | 1.89 (1.38–2.59) | <0.001 | 1.44 (0.83–2.51) | 0.19 |
| Intensive care procedures on admission | ||||||
| Nasogastric tube | 1.14 (0.79–1.66) | 0.48 | 0.69 (0.51–0.92) | 0.01 | 0.83 (0.52–1.32) | 0.42 |
| Respiratory support | 1.34 (0.93–1.92) | 0.11 | - | - | 0.91 (0.58–1.43) | 0.69 |
Multivariate hazard ratios for risk factors for acquired colonization with AROs, according to Cox regression analysis.
| Variables | Nasal colonization (N = 123) | Rectal colonization (N = 199) | Endotracheal colonization (N = 80) | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Admission for tetanus disease | 0.46 (0.29–0.74) | 0.001 | 0.39 (0.27–0.56) | <0.001 | 0.67 (0.33–1.36) | 0.27 |
| Charlson Comorbidity Index score | 1.14 (0.97–1.35) | 0.12 | 1.13 (1.01–1.25) | 0.04 | 1.42 (1.03–1.94) | 0.03 |
| Admission colonization status | ||||||
| Admission nasal colonization | 0.57 (0.32–1.01) | 0.05 | - | - | - | - |
| Admission rectal colonization | - | - | 1.19 (0.80–1.76) | 0.40 | - | - |
| Admission endotracheal colonization | - | - | - | - | 0.76 (0.40–1.45) | 0.41 |
| Receipt of antimicrobial treatment on admission | 1.28 (0.80–2.04) | 0.31 | 1.19 (0.84–1.71) | 0.33 | 1.20 (0.66–2.18) | 0.55 |
| Intensive care procedures on admission | ||||||
| Nasogastric tube | 1.05 (0.68–1.61) | 0.83 | 0.62 (0.46–0.83) | 0.002 | 0.80 (0.48–1.33) | 0.40 |
| Respiratory support | 1.16 (0.77–1.75) | 0.49 | - | - | 0.82 (0.50–1.35) | 0.45 |
Fig 3Number of isolates causing hospital-acquired infections. Sensitive pathogens are represented by the black color. AROs are shown by the grey color.
Subsequent hospital-acquired infections and prior colonization (either admission colonization or acquired colonization) with the same organisms among ICU patients.
| Bacteria | Hospital-acquired infections (n) | Prior colonization (n, %) | |
|---|---|---|---|
| Yes | No | ||
| | |||
Univariate hazard ratios for risk factors of hospital-acquired infections, according to Cox regression analysis.
| Variables | Pneumonia (N = 44) | Urinary tract infection (N = 38) | Bloodstream infection (N = 15) | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Admission for tetanus disease | 0.31 (0.16–0.62) | 0.001 | 1.38 (0.52–5.13) | 0.55 | 0.34 (0.12–1.08) | 0.07 |
| Charlson Comorbidity Index score | 1.28 (0.92–1.62) | 0.13 | 0.87 (0.37–1.41) | 0.66 | 1.31 (0.86–1.74) | 0.17 |
| Prior colonization status | ||||||
| Prior nasal colonization | 0.51 (0.22–1.33) | 0.16 | - | - | - | - |
| Prior rectal colonization | - | - | 0.49 (0.06–63.59) | 0.66 | 0.52 (0.06–68.40) | 0.69 |
| Prior endotracheal colonization | 0.77 (0.40–1.55) | 0.45 | - | - | - | - |
| Intensive care procedures on admission | ||||||
| Urinary catheter | - | - | 0.83 (0.41–1.64) | 0.60 | - | - |
| Respiratory support | 1.30 (0.71–2.38) | 0.39 | - | - | - | - |
| Vascular catheters | - | - | - | - | 5.06 (1.45–15.22) | 0.01 |
Multivariate hazard ratios for risk factors of hospital-acquired infections, according to Cox regression analysis.
| Variables | Pneumonia (N = 44) | Urinary tract infection (N = 38) | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Admission for tetanus disease | 0.33 (0.16–0.67) | 0.002 | 1.25 (0.41–4.88) | 0.72 |
| Charlson Comorbidity Index score | 1.04 (0.71–1.53) | 0.84 | 0.93 (0.39–1.47) | 0.82 |
| Prior colonization status | ||||
| Prior nasal colonization | 0.47 (0.16–1.37) | 0.17 | - | - |
| Prior rectal colonization | - | - | 0.50 (0.06–64.94) | 0.67 |
| Prior endotracheal colonization | 0.84 (0.37–1.90) | 0.69 | - | - |
| Intensive care procedures on admission | ||||
| Urinary catheter | - | - | 0.85 (0.41–1.68) | 0.64 |
| Respiratory support | 1.28 (0.65–2.55) | 0.48 | - | - |
| Vascular catheters | - | - | - | - |